COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT04539275

Edward N Janoff, MD

Edward.Janoff@va.gov

2020-09-04

Terminated

RCT

Randomized

Parallel

Blind label

multi-center

Treatment

inclusion criteria: veterans must meet all of the following criteria to be eligible to participate: admitted to a participating va clinical site with symptoms suggestive of sars-cov-2 infection. participant (or legally authorized representative) provides informed consent prior to initiation of any study procedures. participant (or legally authorized representative) understands and agrees to comply with planned study procedures. veteran 18 years of age at time of screening. has laboratory-confirmed sars-cov-2 infection as determined by polymerase chain reaction (pcr) or antigen test, as documented by either of the following: (1)reverse transcription polymerase chain reaction (rt-pcr) or antigen positive (nasopharyngeal, oropharyngeal, saliva, lower respiratory) in sample collected 72 hours prior to screening; (2)rt-pcr or antigen positive in sample collected > 72 hours but 168 hours (i.e. 7 days) prior to screening, documented inability to obtain a repeat sample (e.g. due to lack of testing supplies, limited testing capacity, results taking > 24 hours, etc.), and progressive disease suggestive of ongoing sars-cov-2 infection. 6.requiring oxygen by nasal cannula or by face-mask as a new treatment (or if previously on home oxygen, at a liter flow at least 2 lpm greater than home prescription), but not on humidified heated high-flow nasal cannula (hhhfnc) at 15 lpm. 7.can be randomized within 72 hours of hospital admission. 8.agrees not to participate in another therapeutic clinical trial for the treatment of covid-19 or sars-cov-2 through day 29 without approval from the investigator(s). taking part in other research studies, including those unrelated to sars-cov-2, without first discussing it with the investigators of this study may invalidate the results of this study, as well as that of the other study.

an individual who meets any of the following criteria will be excluded from participation in this study: respiratory failure requiring mechanical ventilation, non-invasive ventilation including continuous positive airway pressure (cpap) (for an indication other than previously diagnosed sleep apnea and maintained on outpatient settings), or extra-corporeal membrane oxygenation or anticipated to require any of those treatments or to die within 24 hours. anticipated discharge from the hospital or transfer to another hospital that is not a study site within 72 hours. history of previous transfusion reaction. previously documented serum immunoglobulin a (iga) deficiency (<7 mg/dl) documented to have received convalescent plasma in the last 60 days.

2

VA Office of Research and Development

18

100

Puerto Rico;United States

Moderate/severe disease at enrollment

4: Moderate/severe disease at enrollment

75

Proportion of participants developing acute hypoxemic respiratory failure or all-cause death

None

Phase 3

[{"arm_notes": "", "treatment_id": 322, "treatment_name": "Convalescent plasma", "treatment_type": "Convalescent plasma", "pharmacological_treatment": "Biological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]